Good morning, Boston, and Happy Hobbit Day. Here are the five things you need to know in Boston business news to start your workday.
An FDA advisory committee late yesterday unanimously rejected a drug-and-device combination made by a Boston biotech, which the agency had already rejected twice, Rowan Walrath reports.
Should the MBTA’s Mattapan trolley be considered “rapid transit”? The answer, Greg Ryan reports, could determine whether Milton’s new zoning under the MBTA Communities…
